Synonyms: CBR-2092 | TNP-2092
Compound class:
Synthetic organic
Comment: Rifaquizinone (formerly CBR-2092, then TNP-2092) is a rifamycin-quinolone hybrid antibacterial compound [2]. It exerts combined effects on bacterial RNA polymerase, DNA gyrase and DNA topoisomerase IV, although RNA polymerase has been reporetd as the primary cellular target [4]. Rifaquizinone was developed for potential to treat biofilm associated infections such as those caused by staphylococci [3-4]. Initial development was by Cumbre Pharmaceuticals, but it is now being taken forward by TenNor Therapeutics, hence the change in research code.
|
|
No information available. |
Summary of Clinical Use |
TenNor Therapeutics has received FDA Orphan Drug Designation for rifaquizinone to treat prosthetic joint infections [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04294862 | Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty | Phase 1 Interventional | TenNor Therapeutics Limited | ||
NCT03964493 | TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection | Phase 2 Interventional | TenNor Therapeutics Limited |